Wolfe Daniel N, Taylor Marva J, Zarrabian Amanda G
Division of CBRN Countermeasures, Biomedical Advanced Research and Development Authority , Washington, DC, USA.
Hum Vaccin Immunother. 2020 Nov 1;16(11):2855-2860. doi: 10.1080/21645515.2020.1741313. Epub 2020 Apr 10.
The 2014-2016 Ebola virus epidemic in West Africa triggered extensive investments from public and private partners in an attempt to slow the spread of disease and bring the outbreak under control. This significantly accelerated the pace of development of countermeasures against Zaire ebolavirus that enabled vaccines to be a part of an effective response to the most recent 2018-2019 outbreak in the Democratic Republic of the Congo. However, there remain urgent and unmet needs for medical countermeasures against other members of the Filoviridae family that cause viral hemorrhagic fevers. To improve the national and global preparedness posture for viral hemorrhagic fevers, a renewed emphasis is being placed on developing vaccines for filoviruses other than Zaire ebolavirus. Here we discuss lessons learned from the West Africa epidemic and how those lessons apply to the development of vaccine candidates for other filoviruses, specifically Sudan ebolavirus and Marburg virus. This commentary will highlight some of the key product development gaps to address in preparation for future disease outbreaks caused by these viruses.
2014 - 2016年西非埃博拉病毒疫情引发了公共和私人合作伙伴的大量投资，试图减缓疾病传播并控制疫情。这极大地加快了针对扎伊尔埃博拉病毒对策的研发速度，使得疫苗能够成为应对刚果民主共和国最近一次2018 - 2019年疫情的有效手段之一。然而，对于预防其他导致病毒性出血热的丝状病毒科成员的医学对策，仍存在迫切且未得到满足的需求。为了改善国家和全球对病毒性出血热的防范态势，目前正重新强调研发针对除扎伊尔埃博拉病毒之外的其他丝状病毒的疫苗。在此，我们将讨论从西非疫情中吸取的经验教训，以及这些经验如何应用于研发针对其他丝状病毒（特别是苏丹埃博拉病毒和马尔堡病毒）的候选疫苗。本评论将着重指出一些关键的产品研发差距，以便为应对未来由这些病毒引发的疾病爆发做好准备。
